NCT02101333View on ClinicalTrials.gov

Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis

PHASE3CompletedINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

June 10, 2014

Primary Completion Date

December 10, 2018

Study Completion Date

February 1, 2019

Conditions

TAKAYASU ARTERITIS

Interventions

DRUG

Tocilizumab

intravenous injection 8 mg/kg, monthly during 6 months

Trial Locations (1)

75012

Department of internal medicine, Saint-Antoine

Sponsors

Collaborators (1)

Chugai Pharmaceutical

All Listed Sponsors

collaborator

Chugai Pharmaceutical

INDUSTRY

lead

Assistance Publique - Hôpitaux de Paris

OTHER